United Therapeutics (NASDAQ:UTHR) vs. Shineco (NASDAQ:SISI) Head to Head Survey

United Therapeutics (NASDAQ:UTHR) and Shineco (NASDAQ:SISI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for United Therapeutics and Shineco, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0	5	10	0	2.67
Shineco	1	0	0	0	1.00

United Therapeutics presently has a consensus price target of $457.21, suggesting a potential upside of 5.79%. Given United Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe United Therapeutics is more favorable than Shineco.

Profitability

This table compares United Therapeutics and Shineco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.36%	18.73%	16.49%
Shineco	-380.55%	-79.89%	-33.01%

Risk & Volatility

United Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Shineco has a beta of -0.82, meaning that its stock price is 182% less volatile than the S&P 500.

Insider and Institutional Ownership

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Shineco shares are held by institutional investors. 10.3% of United Therapeutics shares are held by insiders. Comparatively, 0.0% of Shineco shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares United Therapeutics and Shineco”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$2.88 billion	6.78	$1.20 billion	$25.62	16.87
Shineco	$9.60 million	0.04	-$22.45 million	N/A	N/A

United Therapeutics has higher revenue and earnings than Shineco.

Summary

United Therapeutics beats Shineco on 12 of the 12 factors compared between the two stocks.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.